• The total number of VTE events across the countries under study will increase by 26%, from 1.9 million in 2016 to 2.4 million in 2026.
  • With 69% of VTE events across the countries under study being provoked rather than idiopathic and 23% being associated with cancer, reductions in VTE events are feasible with prophylaxis among high-risk groups.
  • Similar to other regions, 18% of VTE events across the countries under study are recurrent, with the remainder being first-ever events.

Table of contents

  • Venous Thromboembolism - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Overview
          • VTE Events per 100,000 People of All Ages in 2016 and 2026
          • Relative Sizes of the Contributing Factors to the Trend in VTE Events over the Next Ten Years
          • Number of Additional VTE Events Incurred Over the Period 2016-2026 Across the Countries Under Study
          • VTE Events in 2016 by Subtype
      • Epidemiology Data
      • Methods
        • Diagnosed Events of VTE
        • VTE Events by Etiology
        • VTE Events by Cancer Association
        • VTE Events by Recurrence
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of VTE
          • Studies Excluded from the Analysis of VTE
        • Risk/Protective Factors
          • Risk/Protective Factors for VTE
        • Bibliography

    Author(s): Lade Ayodele; Emma McFadden, PhD

    Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets.

    Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a Ph.D. in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.

    Emma McFadden, Ph.D., is a Director within the Central Nervous System/Ophthalmology disorders group. Her main focus is on ophthalmic indications, such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, although she has authored research across a number of other indications, including multiple sclerosis and epilepsy. 

    Prior to joining Decision Resources Group, Emma earned a B.A. in neuroscience and a Ph.D. in biochemistry from Trinity College Dublin.